# PureCycle Technologies, Inc.: financial statements, quarterly

PCT · Nasdaq · CIK 1830033 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pct.md) · [Financials](/companies/pct/financials.md) · [Filings](/companies/pct/filings.md) · [Insiders](/companies/pct/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pct/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-065671.md) | [0.0](/filings/0000950170-25-105036.md) | [0.0](/filings/0001193125-25-269651.md) | [0.0 d](/filings/0001193125-26-076801.md) | [1.6](/filings/0001830033-26-000014.md) | [1.7](/filings/0001830033-26-000026.md) | [2.4](/filings/0001193125-25-269651.md) | [2.7 d](/filings/0001193125-26-076801.md) | [4.1](/filings/0001830033-26-000014.md) | [4.5](/filings/0001830033-26-000026.md) |
| Research and development | $m | [1.6](/filings/0000950170-24-127556.md) | [1.7 d](/filings/0001193125-26-076801.md) | [1.8](/filings/0000950170-25-065671.md) | [1.6](/filings/0000950170-25-105036.md) | [1.5](/filings/0001193125-25-269651.md) | [1.5 d](/filings/0001193125-26-076801.md) | [1.6](/filings/0001830033-26-000014.md) | [1.4](/filings/0001830033-26-000026.md) | [1.4](/filings/0001193125-25-269651.md) | [1.5 d](/filings/0001193125-26-076801.md) | [1.6](/filings/0001830033-26-000014.md) | [1.4](/filings/0001830033-26-000026.md) |
| Selling, general and administrative | $m | [13.0](/filings/0000950170-24-127556.md) | [16.2 d](/filings/0001193125-26-076801.md) | [16.0](/filings/0000950170-25-065671.md) | [16.1](/filings/0000950170-25-105036.md) | [12.8](/filings/0001193125-25-269651.md) | [8.3 d](/filings/0001193125-26-076801.md) | [13.7](/filings/0001830033-26-000014.md) | [15.8](/filings/0001830033-26-000026.md) | [10.4](/filings/0001193125-25-269651.md) | [18.8 d](/filings/0001193125-26-076801.md) | [13.0](/filings/0001830033-26-000014.md) | [9.6](/filings/0001830033-26-000026.md) |
| Operating income | $m | not reported | not reported | [(39.0)](/filings/0000950170-25-065671.md) | [(39.9)](/filings/0000950170-25-105036.md) | [(31.3)](/filings/0001193125-25-269651.md) | [(35.2) d](/filings/0001193125-26-076801.md) | [(37.7)](/filings/0001830033-26-000014.md) | [(45.6)](/filings/0001830033-26-000026.md) | [(38.9)](/filings/0001193125-25-269651.md) | [(59.2) d](/filings/0001193125-26-076801.md) | [(41.8)](/filings/0001830033-26-000014.md) | [(41.3)](/filings/0001830033-26-000026.md) |
| Interest expense | $m | [10.8](/filings/0001830033-23-000080.md) | [16.5 d](/filings/0001830033-24-000029.md) | [15.1](/filings/0000950170-24-055747.md) | [12.1](/filings/0000950170-24-093899.md) | [14.6](/filings/0001193125-25-269651.md) | [15.2 d](/filings/0001193125-26-076801.md) | [15.1](/filings/0001830033-26-000014.md) | [17.6](/filings/0001830033-26-000026.md) | [16.2](/filings/0001193125-25-269651.md) | [15.5 d](/filings/0001193125-26-076801.md) | [15.4](/filings/0001830033-26-000014.md) | [15.4](/filings/0001830033-26-000026.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-127556.md) | [0.7 d](/filings/0001193125-26-076801.md) | [0.0](/filings/0000950170-25-065671.md) | [0.0](/filings/0000950170-25-105036.md) | [0.0](/filings/0001193125-25-269651.md) | [(0.1) d](/filings/0001193125-26-076801.md) | [0.0](/filings/0001830033-26-000014.md) | [0.0](/filings/0001830033-26-000026.md) | [0.0](/filings/0001193125-25-269651.md) | [1.0 d](/filings/0001193125-26-076801.md) | [0.0](/filings/0001830033-26-000014.md) | [0.0](/filings/0001830033-26-000026.md) |
| Net income | $m | [8.5](/filings/0000950170-24-127556.md) | [(29.0) d](/filings/0001193125-26-076801.md) | [(85.6)](/filings/0001193125-25-269651.md) | [(48.2)](/filings/0001193125-25-269651.md) | [(90.6)](/filings/0001193125-25-269651.md) | [(64.7) d](/filings/0001193125-26-076801.md) | [8.8](/filings/0001830033-26-000026.md) | [(144)](/filings/0001830033-26-000026.md) | [(28.4)](/filings/0001193125-25-269651.md) | [(18.8) d](/filings/0001193125-26-076801.md) | [(33.4)](/filings/0001830033-26-000026.md) | [(142)](/filings/0001830033-26-000026.md) |
| Diluted EPS | $ per share | [0.03](/filings/0000950170-24-127556.md) | not reported | [(0.52)](/filings/0000950170-25-065671.md) | [(0.29)](/filings/0000950170-25-105036.md) | [(0.54)](/filings/0001193125-25-269651.md) | not reported | [0.05](/filings/0001830033-26-000014.md) | [(0.81)](/filings/0001830033-26-000026.md) | [(0.31)](/filings/0001193125-25-269651.md) | not reported | [(0.21)](/filings/0001830033-26-000014.md) | [(0.80)](/filings/0001830033-26-000026.md) |
| Basic EPS | $ per share | [0.05](/filings/0000950170-24-127556.md) | not reported | [(0.52)](/filings/0000950170-25-065671.md) | [(0.29)](/filings/0000950170-25-105036.md) | [(0.54)](/filings/0001193125-25-269651.md) | not reported | [0.05](/filings/0001830033-26-000014.md) | [(0.81)](/filings/0001830033-26-000026.md) | [(0.19)](/filings/0001193125-25-269651.md) | not reported | [(0.21)](/filings/0001830033-26-000014.md) | [(0.80)](/filings/0001830033-26-000026.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [199](/filings/0000950170-24-127556.md) | [73.4](/filings/0001193125-26-076801.md) | [25.0](/filings/0000950170-25-065671.md) | [10.9](/filings/0000950170-25-105036.md) | [83.7](/filings/0001193125-25-269651.md) | [15.7](/filings/0001193125-26-076801.md) | [22.5](/filings/0001830033-26-000014.md) | [284](/filings/0001830033-26-000026.md) | [234](/filings/0001193125-25-269651.md) | [157](/filings/0001193125-26-076801.md) | [90.2](/filings/0001830033-26-000014.md) | [165](/filings/0001830033-26-000026.md) |
| Current assets | $m | [257](/filings/0001830033-23-000080.md) | [163](/filings/0000950170-25-028422.md) | [51.2](/filings/0000950170-24-055747.md) | [31.9](/filings/0000950170-24-093899.md) | [101](/filings/0000950170-24-127556.md) | [53.9](/filings/0001193125-26-076801.md) | [49.7](/filings/0000950170-25-065671.md) | [315](/filings/0000950170-25-105036.md) | [265](/filings/0001193125-25-269651.md) | [198](/filings/0001830033-26-000026.md) | [146](/filings/0001830033-26-000014.md) | [261](/filings/0001830033-26-000026.md) |
| Total assets | $m | [1,072](/filings/0001830033-23-000080.md) | [1,039](/filings/0000950170-25-028422.md) | [734](/filings/0000950170-24-055747.md) | [720](/filings/0000950170-24-093899.md) | [789](/filings/0000950170-24-127556.md) | [798](/filings/0001193125-26-076801.md) | [787](/filings/0000950170-25-065671.md) | [1,042](/filings/0000950170-25-105036.md) | [989](/filings/0001193125-25-269651.md) | [923](/filings/0001830033-26-000026.md) | [886](/filings/0001830033-26-000014.md) | [1,003](/filings/0001830033-26-000026.md) |
| Current liabilities | $m | [52.0](/filings/0001830033-23-000080.md) | [55.6](/filings/0000950170-25-028422.md) | [43.6](/filings/0000950170-24-055747.md) | [47.6](/filings/0000950170-24-093899.md) | [58.3](/filings/0000950170-24-127556.md) | [90.9](/filings/0001193125-26-076801.md) | [90.6](/filings/0000950170-25-065671.md) | [147](/filings/0000950170-25-105036.md) | [118](/filings/0001193125-25-269651.md) | [87.6](/filings/0001830033-26-000026.md) | [85.6](/filings/0001830033-26-000014.md) | [100](/filings/0001830033-26-000026.md) |
| Total liabilities | $m | [630](/filings/0001830033-23-000080.md) | [619](/filings/0000950170-25-028422.md) | [397](/filings/0000950170-24-055747.md) | [428](/filings/0000950170-24-093899.md) | [547](/filings/0000950170-24-127556.md) | [618](/filings/0001193125-26-076801.md) | [549](/filings/0000950170-25-065671.md) | [650](/filings/0000950170-25-105036.md) | [622](/filings/0001193125-25-269651.md) | [572](/filings/0001830033-26-000026.md) | [569](/filings/0001830033-26-000014.md) | [672](/filings/0001830033-26-000026.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [7.1](/filings/0001830033-23-000080.md) | [9.1](/filings/0000950170-25-028422.md) | [3.2](/filings/0000950170-24-055747.md) | [3.9](/filings/0000950170-24-093899.md) | [10.8](/filings/0000950170-24-127556.md) | [12.9](/filings/0000950170-25-028422.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [446](/filings/0000950170-24-127556.md) | [420](/filings/0001193125-26-076801.md) | [337](/filings/0001193125-25-269651.md) | [292](/filings/0001193125-25-269651.md) | [241](/filings/0001193125-25-269651.md) | [180](/filings/0001830033-26-000026.md) | [238](/filings/0001830033-26-000026.md) | [98.9](/filings/0001830033-26-000026.md) | [68.2](/filings/0001193125-25-269651.md) | [45.9](/filings/0001830033-26-000026.md) | [7.4](/filings/0001830033-26-000026.md) | [15.5](/filings/0001830033-26-000026.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.9) d](/filings/0000950170-24-127556.md) | [(33.6) d](/filings/0001193125-26-076801.md) | [(39.2)](/filings/0000950170-25-065671.md) | [(40.4) d](/filings/0000950170-25-105036.md) | [(33.4) d](/filings/0001193125-25-269651.md) | [(31.8) d](/filings/0001193125-26-076801.md) | [(38.9)](/filings/0001830033-26-000014.md) | [(36.7) d](/filings/0001830033-26-000026.md) | [(38.5) d](/filings/0001193125-25-269651.md) | [(28.7) d](/filings/0001193125-26-076801.md) | [(42.7)](/filings/0001830033-26-000014.md) | [(50.0) d](/filings/0001830033-26-000026.md) |
| Capital expenditure | $m | [18.4 d](/filings/0000950170-24-127556.md) | [11.2 d](/filings/0001193125-26-076801.md) | [14.3](/filings/0000950170-25-065671.md) | [10.4 d](/filings/0000950170-25-105036.md) | [9.3 d](/filings/0001193125-25-269651.md) | [21.6 d](/filings/0001193125-26-076801.md) | [15.0](/filings/0001830033-26-000014.md) | [8.6 d](/filings/0001830033-26-000026.md) | [3.9 d](/filings/0001193125-25-269651.md) | [13.3 d](/filings/0001193125-26-076801.md) | [3.4](/filings/0001830033-26-000014.md) | [31.7 d](/filings/0001830033-26-000026.md) |
| Share repurchases | $m | [0.8 d](/filings/0000950170-24-127556.md) | [0.2 d](/filings/0001193125-26-076801.md) | [0.6](/filings/0000950170-25-065671.md) | [0.1 d](/filings/0000950170-25-105036.md) | [0.5 d](/filings/0001193125-25-269651.md) | [0.4 d](/filings/0001193125-26-076801.md) | [1.7](/filings/0001830033-26-000014.md) | [1.1 d](/filings/0001830033-26-000026.md) | [1.7 d](/filings/0001193125-25-269651.md) | [0.4 d](/filings/0001193125-26-076801.md) | [2.2](/filings/0001830033-26-000014.md) | [0.3 d](/filings/0001830033-26-000026.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [163](/filings/0001830033-23-000080.md) | [164](/filings/0000950170-24-055747.md) | [164](/filings/0000950170-24-093899.md) | [166](/filings/0000950170-24-127556.md) | [164](/filings/0000950170-25-065671.md) | [165](/filings/0000950170-25-105036.md) | [167](/filings/0001193125-25-269651.md) | [179](/filings/0001830033-26-000014.md) | [180](/filings/0001830033-26-000026.md) | [185](/filings/0001193125-25-269651.md) | [180](/filings/0001830033-26-000014.md) | [184](/filings/0001830033-26-000026.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 200,904,810 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001830033-26-000026.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.